Encoraf 75 MG (Encorafenib)

Basic Product Information of Encoraf (Encorafenib) 75mg

How Encoraf (Encorafenib) Works

Encoraf contains Encorafenib, a potent and selective inhibitor of the BRAF kinase. BRAF is a key signalling protein within the RAS-RAF-MEK-ERK (MAPK) pathway, which normally transmits controlled growth signals from the cell surface to the nucleus. When the BRAF gene carries a V600E or V600K mutation, the resulting kinase becomes permanently switched on, driving continuous proliferation signals that allow tumour cells to grow and survive without normal regulation.

Encorafenib binds the mutated BRAF kinase with very high potency and an unusually long target residence time, meaning it stays bound to the enzyme far longer than earlier-generation BRAF inhibitors. This sustained inhibition suppresses downstream MEK and ERK phosphorylation, halting the growth signal at its source and triggering tumour cell death in BRAF V600-mutant cancers.

Because tumours can escape single-agent BRAF blockade by reactivating the pathway further downstream, Encoraf is given in combination: with the MEK inhibitor binimetinib in melanoma and non-small cell lung cancer, and with the anti-EGFR antibody cetuximab in colorectal cancer, where EGFR feedback signalling is the dominant escape route. This dual blockade produces deeper, more durable pathway suppression and improves tolerability compared with BRAF inhibition alone.

Indications for Encoraf (Encorafenib)

Encoraf (Encorafenib) is indicated for the following conditions, in each case only where a BRAF V600 mutation has been confirmed by a validated diagnostic test:

Benefits of Encoraf (Encorafenib) 75mg

How to Take Encoraf (Encorafenib)

Monitoring and Dosage Adjustments

Structured monitoring is essential throughout Encoraf therapy. Patients require regular dermatological examination before treatment, every two months during treatment, and for up to six months after the final dose, because BRAF inhibitors are associated with new primary cutaneous malignancies including cutaneous squamous cell carcinoma, keratoacanthoma, and new primary melanoma. Left ventricular ejection fraction should be assessed at baseline, after one month, and every two to three months thereafter when Encoraf is combined with binimetinib.

Additional monitoring includes liver function tests (ALT, AST, bilirubin) at baseline and monthly, serum creatine phosphokinase and creatinine for rhabdomyolysis, ECG and serum electrolytes including potassium and magnesium for QT interval prolongation, and ophthalmological assessment at any report of visual disturbance, given the risk of uveitis and, in combination with binimetinib, serous retinopathy. Patients should also be assessed for signs of venous thromboembolism, bleeding, and interstitial lung disease. Dose reduction, interruption, or discontinuation is managed by the oncologist according to the graded severity of any adverse reaction.

Drug Interactions and Important Information

Encorafenib is primarily metabolised by CYP3A4. Concomitant use of strong or moderate CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice should be avoided, as they substantially increase Encorafenib exposure and the risk of toxicity. If co-administration is unavoidable, dose reduction under oncologist supervision is required. Conversely, strong or moderate CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, and St John’s Wort should be avoided because they reduce Encorafenib exposure and may compromise efficacy.

Encorafenib is itself an inducer of CYP3A4, CYP2B6, and CYP2C9. Clinically, this means it can reduce the effectiveness of hormonal contraceptives, so women of childbearing potential must use an effective non-hormonal contraceptive method during treatment and for at least two weeks after the final dose. Caution is also required with warfarin and other narrow therapeutic index CYP2C9 substrates.

Because Encorafenib can prolong the QT interval, concurrent use with other QT-prolonging medicines such as certain antiarrhythmics, macrolide antibiotics, fluoroquinolones, and antipsychotics requires ECG monitoring and correction of electrolyte abnormalities. Always give your oncologist a complete list of all prescription medicines, over-the-counter products, supplements, and herbal remedies before starting Encoraf.

Side Effects and Precautions

Who Should Use Encoraf (Encorafenib)?

Encoraf is intended for adult patients with a molecularly confirmed BRAF V600E or V600K mutation in unresectable or metastatic melanoma, or a confirmed BRAF V600E mutation in metastatic colorectal cancer or metastatic non-small cell lung cancer. It is prescribed exclusively by medical oncologists working within a service capable of molecular tumour profiling, cardiac imaging, and ophthalmological and dermatological review.

Encoraf is not appropriate for patients whose tumours are BRAF wild-type, for patients with hypersensitivity to Encorafenib, or for patients who are pregnant or breastfeeding. It requires caution in patients with pre-existing cardiac dysfunction, significant hepatic impairment, uncontrolled electrolyte abnormalities, or a history of thromboembolic disease. Because the partner agent is integral to the regimen, patients must also be able to access and tolerate binimetinib or cetuximab alongside Encoraf.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is an established Bangladeshi pharmaceutical manufacturer with a substantial and rapidly expanding oncology and specialty medicine portfolio. The company operates dedicated manufacturing facilities built to current Good Manufacturing Practice standards, with segregated oncology production lines and in-house analytical quality control for identity, assay, dissolution, and impurity profiling on every batch.

Everest’s oncology range covers targeted small-molecule therapies across lung, breast, colorectal, haematological, and skin cancers, including tyrosine kinase inhibitors, MEK and BRAF inhibitors, and hormonal agents. Encoraf (Encorafenib 75mg) sits within this targeted therapy range and is designed to work alongside Everest’s own MEK inhibitor product for combination BRAF/MEK regimens, giving prescribers a complete and cost-controlled treatment pathway from a single manufacturer.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted therapy medications sourced from Bangladesh’s leading manufacturers. We make Encoraf (Encorafenib) 75mg accessible to patients, oncologists, and institutional buyers worldwide through reliable worldwide shipping, with full order tracking and documentation support. Whether you are located in South Asia, the Middle East, Africa, Europe, Latin America, or beyond, our team can advise on pricing, availability, multi-month supply planning, and the documentation your country requires for personal import. Contact us directly via WhatsApp, phone, or WeChat for a quotation.

Why Choose Encoraf (Encorafenib) from Mediaid Pharmacy?

BRAF-targeted therapy transformed outcomes in BRAF V600-mutant cancers, but originator pricing has kept it out of reach for a large share of patients worldwide. Encoraf delivers the same active molecule as Braftovi by Array BioPharma and Pfizer, with the same once-daily oral BRAF V600 inhibition, at a dramatically lower cost. Manufactured by Everest Pharmaceuticals Ltd. to current GMP standards and supplied globally by Mediaid Pharmacy, Encoraf allows oncologists and patients to sustain a full course of BRAF-targeted treatment rather than abandoning it on cost grounds. For patients with confirmed BRAF V600 mutation-positive melanoma, colorectal cancer, or non-small cell lung cancer seeking a proven, affordable, and reliably supplied Encorafenib option with worldwide delivery, Encoraf from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Encoraf (Encorafenib)